Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM
- PMID: 8405695
- DOI: 10.2337/diab.42.11.1559
Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM
Abstract
To examine whether overnight suppression of free fatty acid levels reduces hepatic glucose production, 20 NIDDM patients were given a slow-release formulation of the antilipolytic agent acipimox, in a double-blind crossover manner at bedtime for 4 wk. During acipimox treatment, serum free fatty acid concentrations were suppressed between 2400 and 0600 by 64% (P < 0.001), but no reduction in hepatic glucose production was observed (2.16 +/- 0.16 vs. 2.23 +/- 0.16 mg.kg-1 x min-1, acipimox vs. placebo). In contrast, from 0800 to 2000 a sustained 50% rise occurred in serum free fatty acids (P < 0.001). As a consequence, the 24-h area under the free fatty acid curve was similar during both treatment periods. In the morning, the rise in free fatty acid concentration occurred despite identical serum acipimox concentrations as those measured at midnight, when free fatty acid levels were suppressed. Although energy expenditure was higher (P < 0.05) during periods of elevated free fatty acid levels, the sums of energy expenditure measured in the morning and in the evening were similar during the acipimox and placebo periods. To exclude that the free fatty acid rise was caused by administration of acipimox only once at bedtime, additional experiments were performed administering acipimox every 2 h for 4 days. Despite similar acipimox concentration on day 1 and day 4 of this frequent dosing regimen, the free fatty acid concentrations were significantly higher on day 4 compared with day 1 (P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.Diabetes. 1993 Dec;42(12):1694-9. doi: 10.2337/diab.42.12.1694. Diabetes. 1993. PMID: 8243814 Clinical Trial.
-
Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.Diabet Med. 1993 Dec;10(10):950-7. doi: 10.1111/j.1464-5491.1993.tb00011.x. Diabet Med. 1993. PMID: 8306591
-
Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM.Diabetes. 1989 May;38(5):580-8. doi: 10.2337/diab.38.5.580. Diabetes. 1989. PMID: 2653929
-
Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.J Clin Endocrinol Metab. 1994 Mar;78(3):717-21. doi: 10.1210/jcem.78.3.8126147. J Clin Endocrinol Metab. 1994. PMID: 8126147 Clinical Trial.
-
Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.Diabetologia. 1998 Oct;41(10):1127-32. doi: 10.1007/s001250051041. Diabetologia. 1998. PMID: 9794097 Clinical Trial.
Cited by
-
The impact of short-term forearm immobilization and acipimox administration on muscle amino acid metabolism and insulin sensitivity in healthy, young volunteers.bioRxiv [Preprint]. 2023 Oct 12:2023.10.10.561668. doi: 10.1101/2023.10.10.561668. bioRxiv. 2023. Update in: Am J Physiol Endocrinol Metab. 2024 Mar 1;326(3):E277-E289. doi: 10.1152/ajpendo.00345.2023. PMID: 37873346 Free PMC article. Updated. Preprint.
-
Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.J Clin Endocrinol Metab. 2019 Jul 1;104(7):2581-2592. doi: 10.1210/jc.2018-02503. J Clin Endocrinol Metab. 2019. PMID: 30726969 Free PMC article. Clinical Trial.
-
Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule.J Endocr Soc. 2017 May 15;1(7):816-835. doi: 10.1210/js.2017-00092. eCollection 2017 Jul 1. J Endocr Soc. 2017. PMID: 29264533 Free PMC article. Review.
-
Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.Br J Clin Pharmacol. 2017 Dec;83(12):2671-2677. doi: 10.1111/bcp.13384. Epub 2017 Aug 24. Br J Clin Pharmacol. 2017. PMID: 28736944 Free PMC article. Clinical Trial.
-
Acyl Ghrelin Induces Insulin Resistance Independently of GH, Cortisol, and Free Fatty Acids.Sci Rep. 2017 Feb 15;7:42706. doi: 10.1038/srep42706. Sci Rep. 2017. PMID: 28198428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous